Guanethidine |
| Catalog No.GC66202 |
Guanethidine sulphate was synthesized in 1959. Guanethidine is thought to lowing blood pressure by interfering with the metabolism of chemical transmitter substances in post-ganglionic sympathetic nerve fibres.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 55-65-2
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Guanethidine sulphate was synthesized in 1959. Guanethidine is thought to lowing blood pressure
by interfering with the metabolism of chemical transmitter substances in post-ganglionic sympathetic nerve fibres.
Ablation of sympathetic fibers is associated with a loss of rat endothelial cell marker (RECA), but no significant effect of guanethidine was found on the survival of endothelial cells and mesenchymal stem cells in vitro[1].
.
Guanethidine (30 mg/kg, s.c., 1 h) unaffected IL-18 hypernociception in TNFR1(-/-) mice as a sympathetic blocker[2].
.
| Animal Model: | Wild-type (WT) Balb/c,TNFR1(-/-)and IFN-γ-γ(-/-) mice[2]. |
| Dosage: | 30 mg/kg |
| Administration: | Guanethidine (30 mg/kg, s.c., 1 h, diluted in saline) |
| Result: | Pre-treatment with guanethidine (sympathetic blocker) unaffected IL-18 hypernociception in TNFR1(-/-) mice. |
| Cas No. | 55-65-2 | SDF | |
| Formula | C10H22N4 | M.Wt | 198.31 |
| Solubility | Storage | Store at -20°C | |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 5.0426 mL | 25.2131 mL | 50.4261 mL |
| 5 mM | 1.0085 mL | 5.0426 mL | 10.0852 mL |
| 10 mM | 0.5043 mL | 2.5213 mL | 5.0426 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *